Core Insights - A lesser-known Chinese company has developed a new drug that outperforms the world's best-selling cancer medication, highlighting the progress of China's innovative pharmaceutical sector [1] - The Chinese government has been actively promoting the development of innovative drugs, emphasizing the importance of self-reliance in the biopharmaceutical industry [1] Group 1: Industry Development - From 2015 to 2025, China's innovative drug sector has seen a significant increase in research and development investment, streamlined approval processes, and expanded market opportunities, forming a "golden triangle" of technology, policy, and capital [2] - The number of clinical trial applications for innovative drugs in China has increased twelvefold, with notable approvals for domestic PD-1 monoclonal antibodies, HPV vaccines, and PARP inhibitors [2] Group 2: Market Achievements - By 2025, China has approved 76 innovative drugs, surpassing the previous year's total of 48, marking a historical high [5] - The total value of innovative drug licensing transactions in China has exceeded $130 billion, with over 150 transactions, both figures representing record highs [5] Group 3: Accessibility and Affordability - A newly developed diabetes treatment has been included in the national medical insurance directory, costing patients only 10 yuan per day, reflecting the government's commitment to making innovative drugs accessible [6] - The time taken for new drugs to be included in the medical insurance directory has been reduced from approximately five years to about one year, with around 80% of innovative drugs being added within two years of market approval [6]